Lower levels of ERCC1 (excision repair cross-complementation group 1) and thymidylate synthase expression may be predictive of longer survival in patients with metastatic colon cancer, according to a study by Choueiri et al in PLOS One. It was shown that patients with low levels of ERCC1 and...
Patients with colorectal cancer experience significantly higher rates of numbness/tingling but comparable neuropathic pain relative to patients with other cancers, according to a study by Lewis et al in the Journal of Pain and Symptom Management. In addition, numbness/tingling was more likely to be ...
In an analysis of patients with T1 node-positive colon cancer who had previous surgery, adjuvant chemotherapy provided a significant survival advantage, according to a study by Ganapathi et al in Diseases of the Colon and Rectum. However, the investigators noted that a significant minority of this...
Compared with normal colorectal mucosae, nearly half of colorectal tumors showed medium-to-high levels of lecithin retinol acyltransferase (LRAT) hypermethylation, according to the results of a study reported by Cheng et al in Medical Oncology. This finding was noted more frequent in earlier tumor...
Extended colectomy in patients with sporadic colorectal cancer who were younger than age 50, in comparison with segmental resection, did not improve the risk of tumor recurrence or disease-free survival, according to the results of a retrospective study presented by Klos et al in the Journal of...
A “reasonable” delay prior to surgery for colon cancer may not result in worse outcomes, according to the results of a retrospective study presented by Amri et al in the Annals of Surgical Oncology. Flexibility in scheduling surgery may lead to an improvement in the quality and safety...
ALK and ROS1 gene rearrangements, which are known to drive subsets of lung cancer, appear to be present in some colorectal cancers as well, according to the results of a study published in Molecular Cancer Research. The findings by Aisner et al suggest that therapies used to target these two...
Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...